PD-1 inhibition to engage the power of immunity

Sanofi Regeneron came to GENICOS with a molecule (cemiplimab) that had shown compelling efficacy in an area of long unmet need—advanced cutaneous squamous cell carcinoma (CSCC)—a condition that was most common in older men, and in particular those exposed to natural or work-related environmental elements. Our creative captured not just the patient—but hope for that patient in the eye of the treater.